U.S. markets open in 1 hour 35 minutes
  • S&P Futures

    3,803.75
    +13.25 (+0.35%)
     
  • Dow Futures

    30,860.00
    +32.00 (+0.10%)
     
  • Nasdaq Futures

    13,096.00
    +110.50 (+0.85%)
     
  • Russell 2000 Futures

    2,143.30
    -4.00 (-0.19%)
     
  • Crude Oil

    53.59
    +0.61 (+1.15%)
     
  • Gold

    1,850.00
    +9.80 (+0.53%)
     
  • Silver

    25.42
    +0.10 (+0.38%)
     
  • EUR/USD

    1.2101
    -0.0032 (-0.27%)
     
  • 10-Yr Bond

    1.0920
    0.0000 (0.00%)
     
  • Vix

    22.30
    -2.04 (-8.38%)
     
  • GBP/USD

    1.3662
    +0.0028 (+0.20%)
     
  • USD/JPY

    103.8180
    -0.0740 (-0.07%)
     
  • BTC-USD

    34,626.92
    +22.37 (+0.06%)
     
  • CMC Crypto 200

    682.25
    -32.95 (-4.61%)
     
  • FTSE 100

    6,708.50
    -4.45 (-0.07%)
     
  • Nikkei 225

    28,523.26
    -110.20 (-0.38%)
     

Allena Pharmaceuticals to Present at Evercore ISI 2nd Annual HEALTHCONx Conference

NEWTON, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 2nd Annual HEALTHCONx Conference on Tuesday, December 3, 2019 at 3:30 p.m. ET in Boston, MA.

A live audio webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. A replay of the webcast will be available on the Allena website for 30 days following the presentation.

About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com